Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity

Clicks: 345
ID: 117796
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 2 articles by views in cancer immunology, immunotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract is not available for this article.
Login to Search Abstract
Reference Key
teague2019cancercheckpoint Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lindsey M. Kuehm,Kyle J. Wolf,John Zahour,Richard J. DiPaolo,Ryan M. Teague;Lindsey M. Kuehm;Kyle J. Wolf;John Zahour;Richard J. DiPaolo;Ryan M. Teague;
Journal cancer immunology, immunotherapy
Year 2019
DOI
10.1007/s00262-019-02346-4
URL
https://sciprofiles.com/publication/view/1feb5fda94ee6977e9c7462597b902eb
Keywords
melanoma immunotherapy t cell checkpoint blockade tcr diversity

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.